1
 Food and Drug Administration spokesman Jeff Nesbit said 
5002
attribution

2
the agency has turned over evidence in a criminal investigation 
5001
span

3
concerning Vitarine Pharmaceuticals Inc.
2
elaboration-object-attribute-e

4
 to the U.S. Attorney's office in Baltimore.
5002
Same-Unit

5
 Neither Vitarine nor any of the Springfield Gardens, N.Y., company's officials or employees have been charged with any crimes.
5003
elaboration-additional

6
 Vitarine won approval 
5005
span

7
to market a version of a blood pressure medicine 
6
elaboration-object-attribute-e

8
but acknowledged 
9
attribution

9
that it substituted a SmithKline Beecham PLC product as its own in tests.
5006
span

10
 Mr. Nesbit also said 
11
attribution

11
the FDA has asked Bolar Pharmaceutical Co. to recall at the retail level its urinary tract antibiotic.
5009
span

12
 But so far the company hasn't complied with that request, 
5010
span

13
the spokesman said.
12
attribution

14
 Bolar, the subject of a criminal investigation by the FDA and the Inspector General's office of the Health and Human Services Department, only agreed to recall two strengths of its version of Macrodantin as far down as direct customers, mostly wholesalers, 
5013
span

15
Mr. Nesbit said.
14
attribution

16
 Bolar, of Copiague, N.Y., earlier began a voluntary recall of both its 100 milligram and 50 milligram versions of the drug.
5013
elaboration-general-specific

17
 The FDA has said 
5022
attribution

18
it presented evidence 
5016
span

19
it uncovered 
18
elaboration-object-attribute-e

20
to the company 
5017
Same-Unit

21
indicating 
5020
attribution

22
that Bolar substituted the brand-name product for its own 
5020
span

23
to gain government approval
5021
span

24
 to sell generic versions of Macrodantin.
23
elaboration-object-attribute-e

25
 Bolar has denied 
26
attribution-n

26
that it switched the brand-name product for its own in such testing.
5023
span

5001
span
5002
Same-Unit

5002
multinuc
5003
span

5003
span
5004
span

5004
span
5008
span

5005
span
5006
concession

5006
span
5007
span

5007
span
5004
elaboration-general-specific

5008
span
5012
Topic-Drift

5009
span
5011
Contrast

5010
span
5015
concession

5011
multinuc
5025
span

5012
multinuc



5013
span
5015
span

5014
span
5011
Contrast

5015
span
5014
span

5016
span
5017
Same-Unit

5017
multinuc
5022
span

5018
span
5024
Statement-Response

5019
span
5017
elaboration-general-specific-e

5020
span
5019
span

5021
span
22
purpose

5022
span
5018
span

5023
span
5024
Statement-Response

5024
multinuc
5011
elaboration-additional

5025
span
5012
Topic-Drift

